225 related articles for article (PubMed ID: 19391212)
1. MOC-31 exhibits superior reactivity compared with Ber-EP4 in invasive lobular and ductal carcinoma of the breast: a tissue microarray study.
Pai RK; West RB
Appl Immunohistochem Mol Morphol; 2009 May; 17(3):202-6. PubMed ID: 19391212
[TBL] [Abstract][Full Text] [Related]
2. Claudin-4 shows superior specificity for mesothelioma vs non-small-cell lung carcinoma compared with MOC-31 and Ber-EP4.
Naso JR; Churg A
Hum Pathol; 2020 Jun; 100():10-14. PubMed ID: 32333920
[TBL] [Abstract][Full Text] [Related]
3. Reactivity with the EpCAM-specific antibodies MOC-31 and Ber-Ep4 in plasma cell neoplasms: a potential diagnostic pitfall in cytology samples.
Weimholt RC; Sharifai N; Abro B; Vij K; Bernadt C
J Am Soc Cytopathol; 2019; 8(5):265-269. PubMed ID: 31103372
[TBL] [Abstract][Full Text] [Related]
4. The utility of claudin-4 versus MOC-31 and Ber-EP4 in the diagnosis of metastatic carcinoma in cytology specimens.
Najjar S; Gan Q; Stewart J; Sneige N
Cancer Cytopathol; 2023 Apr; 131(4):245-253. PubMed ID: 36522809
[TBL] [Abstract][Full Text] [Related]
5. Novel immunohistochemical markers for the differentiation of lobular and ductal invasive breast carcinomas.
Turashvili G; Bouchal J; Ehrmann J; Fridman E; Skarda J; Kolar Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2007 Jun; 151(1):59-64. PubMed ID: 17690741
[TBL] [Abstract][Full Text] [Related]
6. Claudin-4 immunohistochemistry is a useful pan-carcinoma marker for serous effusion specimens.
Vojtek M; Walsh MD; Papadimos DJ; Shield PW
Cytopathology; 2019 Nov; 30(6):614-619. PubMed ID: 31390089
[TBL] [Abstract][Full Text] [Related]
7. Lobular versus ductal breast neoplasms: the diagnostic utility of p120 catenin.
Dabbs DJ; Bhargava R; Chivukula M
Am J Surg Pathol; 2007 Mar; 31(3):427-37. PubMed ID: 17325485
[TBL] [Abstract][Full Text] [Related]
8. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal mesotheliomas and serous carcinomas: a comparative study.
Ordóñez NG
Mod Pathol; 2006 Jan; 19(1):34-48. PubMed ID: 16056246
[TBL] [Abstract][Full Text] [Related]
9. Monoclonal antibody Ber-EP4: its use in the differential diagnosis of malignant mesothelioma and carcinoma in cell blocks of malignant effusions and FNA specimens.
Maguire B; Whitaker D; Carrello S; Spagnolo D
Diagn Cytopathol; 1994; 10(2):130-4. PubMed ID: 8187591
[TBL] [Abstract][Full Text] [Related]
10. Differentiation of tumours of ductal and lobular origin: I. Proteomics of invasive ductal and lobular breast carcinomas.
Turashvili G; Bouchal J; Burkadze G; Kolár Z
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2005 Jun; 149(1):57-62. PubMed ID: 16170389
[TBL] [Abstract][Full Text] [Related]
11. Ber-EP4 for differentiating adenocarcinoma from reactive and neoplastic mesothelial cells in serous effusions. Comparison with carcinoembryonic antigen, B72.3 and Leu-M1.
Bailey ME; Brown RW; Mody DR; Cagle P; Ramzy I
Acta Cytol; 1996; 40(6):1212-6. PubMed ID: 8960030
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemical utility of claudin-4 versus those of Ber-EP4 and MOC-31 in effusion cytology.
Oda T; Ogata S; Kawaguchi S; Minabe S; Dokyu M; Takahashi H; Kumazawa F; Shimazaki H; Takano M; Hase K; Ozeki Y; Kanoh S; Nakanishi K
Diagn Cytopathol; 2016 Jun; 44(6):499-504. PubMed ID: 27015745
[TBL] [Abstract][Full Text] [Related]
13. Differential sensitivity of estrogen/progesterone receptors and BRST-2 markers in metastatic ductal and lobular breast carcinoma to the skin.
Wallace ML; Smoller BR
Am J Dermatopathol; 1996 Jun; 18(3):241-7. PubMed ID: 8806958
[TBL] [Abstract][Full Text] [Related]
14. Utility of Ber-EP4 and MOC-31 in Basaloid Skin Tumor Detection.
Gill P; Naugler C; Abi Daoud MS
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):584-588. PubMed ID: 29629953
[TBL] [Abstract][Full Text] [Related]
15. MOC-31/Ep-CAM immunoreactivity in Merkel cells and Merkel cell carcinomas.
García-Caballero T; Pintos E; Gallego R; Parrado C; Blanco M; Bjornhagen V; Forteza J; Beiras A
Histopathology; 2003 Nov; 43(5):480-4. PubMed ID: 14636274
[TBL] [Abstract][Full Text] [Related]
16. MOC-31 Antibody Immunolabeling During Mohs Surgery.
Bae E; Saap L; Breen C; Iwamoto S
Dermatol Surg; 2022 Jun; 48(6):595-600. PubMed ID: 35384902
[TBL] [Abstract][Full Text] [Related]
17. Correlation of HER2 overexpression with gene amplification and its relation to chromosome 17 aneuploidy: a 5-year experience with invasive ductal and lobular carcinomas.
Nassar A; Khoor A; Radhakrishnan R; Radhakrishnan A; Cohen C
Int J Clin Exp Pathol; 2014; 7(9):6254-61. PubMed ID: 25337277
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of Ep-CAM AND Her-2/neu overexpression in invasive breast cancer.
Spizzo G; Obrist P; Ensinger C; Theurl I; Dünser M; Ramoni A; Gunsilius E; Eibl G; Mikuz G; Gastl G
Int J Cancer; 2002 Apr; 98(6):883-8. PubMed ID: 11948467
[TBL] [Abstract][Full Text] [Related]
19. Value of mesothelial and epithelial antibodies in distinguishing diffuse peritoneal mesothelioma in females from serous papillary carcinoma of the ovary and peritoneum.
Attanoos RL; Webb R; Dojcinov SD; Gibbs AR
Histopathology; 2002 Mar; 40(3):237-44. PubMed ID: 11895489
[TBL] [Abstract][Full Text] [Related]
20. Value of the Ber-EP4 antibody in differentiating epithelial pleural mesothelioma from adenocarcinoma. The M.D. Anderson experience and a critical review of the literature.
Ordóñez NG
Am J Clin Pathol; 1998 Jan; 109(1):85-9. PubMed ID: 9426522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
